Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$371.12K$371.12K−72.0% vs Q1 2020 Net Income-$54.40M-$54.40MN/M vs Q1 2020 EPS Diluted-$0.27-$0.27N/M vs Q1 2020 Operating Income-$52,554,492N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$53,078,252N/M Margins · derivedOperating margin-14161.1%−12260.0 pt vs Q1 2020
Net margin-14658.9%−12207.2 pt vs Q1 2020
ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end